Journal of Lipid Research
Patient-Oriented and Epidemiological ResearchReduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus
Cited by (0)
M.F. has been supported by grants from the Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology (MEXT) Translational Research Network Program, Uehara Memorial Foundation, Senshin Medical Research Foundation, Japan Diabetes Foundation, Takeda Medical Research Foundation, Ono Medical Research Foundation, Takeda Science Foundation, Akiyama Life Science Foundation, Yamaguchi Endocrine Research Foundation, Naito Foundation Natural Science Scholarship, Suhara Memorial Foundation, and Kondou Kinen Medical Foundation. The authors declare no conflict of interest.
The online version of this article (available at http://www.jlr.org) contains a supplement.
- 1
5-AG, 1,5-anhydroglucitol
- C/EBPα
CCAAT/enhancer binding protein α
- CL
cell lysate
- CM
conditioned medium
- Cr
creatinine
- DPP-4
dipeptidyl peptidase 4
- eGFR
estimated glomerular filtration rate
- FABP
fatty acid binding protein
- FABP4
fatty acid binding protein 4
- GIP
gastric inhibitory polypeptide
- GLP-1
glucagon-like peptide 1
- M/F
male/female
Abbreviations: